{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:08:11Z","timestamp":1780384091556,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00059-024-05252-3","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T15:02:13Z","timestamp":1719327733000},"page":"313-318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Periphere arterielle Verschlusskrankheit (pAVK)","Lower extremity arterial disease (LEAD)"],"prefix":"10.1007","volume":"49","author":[{"given":"Christine","family":"Espinola-Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"5252_CR1","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"V Aboyans","year":"2018","unstructured":"Aboyans\u00a0V, Ricco\u00a0JB, Bartelink\u00a0MEL et\u00a0al (2018) 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart\u00a0J 39:763\u2013816. https:\/\/doi.org\/10.1093\/eurheartj\/ehx095","journal-title":"Eur Heart J"},{"key":"5252_CR2","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/eurheartj\/ehv006","volume":"36","author":"H Reinecke","year":"2015","unstructured":"Reinecke\u00a0H, Unrath\u00a0M, Freisinger\u00a0E et\u00a0al (2015) Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence. Eur Heart\u00a0J 36:932\u2013938","journal-title":"Eur Heart J"},{"key":"5252_CR3","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s00108-009-2364-4","volume":"50","author":"C Espinola-Klein","year":"2009","unstructured":"Espinola-Klein\u00a0C, Savvidis\u00a0S (2009) Periphere arterielle Verschlusskrankheit-Epidemiologie, Klinik und Diagnostik. Internist 50:919\u2013926","journal-title":"Internist"},{"key":"5252_CR4","doi-asserted-by":"publisher","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","volume":"7","author":"P Song","year":"2019","unstructured":"Song\u00a0P, Rudan\u00a0D, Zhu\u00a0Y et\u00a0al (2019) Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health 7:e1020\u2013e1030. https:\/\/doi.org\/10.1016\/S2214-109X(19)30255-4","journal-title":"Lancet Glob Health"},{"key":"5252_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100113","author":"C Rammos","year":"2021","unstructured":"Rammos\u00a0C, Steinmetz\u00a0M, Lortz\u00a0J et\u00a0al (2021) Peripheral artery disease in Germany (2009\u20132018): Prevalence, frequency of specialized ambulatory care and use of guideline recommended therapy. Lancet Reg Health Eur. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100113","journal-title":"Lancet Reg Health Eur"},{"key":"5252_CR6","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1056\/NEJMra1615439","volume":"376","author":"DG Armstrong","year":"2017","unstructured":"Armstrong\u00a0DG, Boulton\u00a0AJM, Bus\u00a0SA (2017) Diabetic Foot Ulcers and Their Recurrence. N\u00a0Engl J Med 376:2367\u20132375","journal-title":"N Engl J Med"},{"key":"5252_CR7","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1016\/j.jvs.2019.02.016","volume":"69","author":"MS Conte","year":"2019","unstructured":"Conte\u00a0MS, Bradbury\u00a0AW, Kolh\u00a0P et\u00a0al (2019) Global vascular guidelines on the management of chronic limb-threatening ischemia. J\u00a0Vasc Surg 69:3S\u2013125S.e40","journal-title":"J Vasc Surg"},{"key":"5252_CR8","first-page":"S1","volume":"Suppl 95","author":"H Lawall","year":"2016","unstructured":"Lawall\u00a0H, Kopp\u00a0I (2016) S3-Leitlinie PAVK. Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. Vasa Suppl 95:S1\u2013S95","journal-title":"Vasa"},{"key":"5252_CR9","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.107.763227","volume":"118","author":"C Espinola-Klein","year":"2008","unstructured":"Espinola-Klein\u00a0C, Rupprecht\u00a0HJ, Bickel\u00a0C et\u00a0al (2008) Different calculations of ankle brachial index and their impact on cardiovascular risk prediction. Circulation 118:961\u2013967","journal-title":"Circulation"},{"key":"5252_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1161\/01.CIR.0000112642.63927.54","volume":"109","author":"HE Resnick","year":"2004","unstructured":"Resnick\u00a0HE, Linsay\u00a0RS, McDermott\u00a0MM et\u00a0al (2004) Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 109:733\u2013739","journal-title":"Circulation"},{"key":"5252_CR11","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1055\/a-2017-7629","volume":"148","author":"C Espinola-Klein","year":"2023","unstructured":"Espinola-Klein\u00a0C (2023) Epidemiology and diagnosis of PAD. Dtsch Med Wochenschr 148:1287\u20131292. https:\/\/doi.org\/10.1055\/a-2017-7629","journal-title":"Dtsch Med Wochenschr"},{"key":"5252_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach\u00a0F, Baigent\u00a0C, Catapano\u00a0AL et\u00a0al (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart\u00a0J 41:111\u2013188","journal-title":"Eur Heart J"},{"key":"5252_CR13","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx\u00a0N, Federici\u00a0M, Sch\u00fctt\u00a0K et\u00a0al (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart\u00a0J 44:4043\u20134140","journal-title":"Eur Heart J"},{"key":"5252_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.117.032031","volume":"137","author":"S Verma","year":"2018","unstructured":"Verma\u00a0S, Mazer\u00a0CD, Al-Omran\u00a0M et\u00a0al (2018) Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type\u00a02 Diabetes Mellitus and Peripheral Artery Disease: A\u00a0Subanalysis of EMPA-REG OUTCOME. Circulation 137:405\u2013407","journal-title":"Circulation"},{"key":"5252_CR15","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/dom.14700","volume":"24","author":"S Verma","year":"2022","unstructured":"Verma\u00a0S, Al-Omran\u00a0M, Leiter\u00a0LA et\u00a0al (2022) Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab 24:1288\u20131299","journal-title":"Diabetes Obes Metab"},{"key":"5252_CR16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal\u00a0B, Perkovic\u00a0V, Mahaffrey\u00a0KW et\u00a0al (2017) Canagliflozin and cardiovascular and renal events in type\u00a02 diabetes. N\u00a0Engl J Med 377:644\u2013657","journal-title":"N Engl J Med"},{"key":"5252_CR17","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1055\/s-0040-1709711","volume":"120","author":"D Pastori","year":"2020","unstructured":"Pastori\u00a0D, Farcomeni\u00a0A, Milanese\u00a0A et\u00a0al (2020) Statins and major adverse limb events in patients with peripheral artery disease: a\u00a0systematic review and metaanalysis. Thromb Haemost 120:866\u2013875","journal-title":"Thromb Haemost"},{"key":"5252_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1177\/1358863X19894055","volume":"25","author":"DG Kokkinidis","year":"2020","unstructured":"Kokkinidis\u00a0DG, Arfaras-Melainis\u00a0A, Giannopoulos\u00a0S et\u00a0al (2020) Statin therapy for reduction of cardiovascular and limb-related events in critical limb ischemia: a\u00a0systematic review and meta-analysis. Vasc Med 25:106\u2013117","journal-title":"Vasc Med"},{"key":"5252_CR19","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1161\/01.CIR.0000090686.57897.F5","volume":"108","author":"ER Mohler","year":"2003","unstructured":"Mohler\u00a0ER, Hiatt\u00a0WR, Creager\u00a0MA (2003) Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108:1481\u20131486","journal-title":"Circulation"},{"key":"5252_CR20","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1093\/eurheartj\/ehab390","volume":"42","author":"V Aboyans","year":"2021","unstructured":"Aboyans\u00a0V, Bauersachs\u00a0R, Mazzolai\u00a0L et\u00a0al (2021) Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a\u00a0consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart\u00a0J 42:4013\u20134024","journal-title":"Eur Heart J"},{"key":"5252_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","volume":"391","author":"SS Anand","year":"2017","unstructured":"Anand\u00a0SS, Bosch\u00a0J, Eikelboom\u00a0JW et\u00a0al (2017) Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391:219\u2013229","journal-title":"Lancet"},{"key":"5252_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100113","author":"C Rammos","year":"2021","unstructured":"Rammos\u00a0C, Steinmetz\u00a0M, Lortz\u00a0J et\u00a0al (2021) Peripheral artery disease in Germany (2009\u20132018): Prevalence, frequency of specialized ambulatory care and use of guideline recommended therapy\u2014a population-based study. Lancet Reg Health Eur. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100113","journal-title":"Lancet Reg Health Eur"},{"key":"5252_CR23","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/eurheartj\/ehad734","volume":"45","author":"L Mazzolai","year":"2024","unstructured":"Mazzolai\u00a0L, Belch\u00a0J, Venermo\u00a0M et\u00a0al (2024) Exercise for chronic symptomatic peripheral arterial disease. Eur Heart\u00a0J 45:1303\u20131321","journal-title":"Eur Heart J"},{"key":"5252_CR24","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa2207899","volume":"387","author":"A Farber","year":"2022","unstructured":"Farber\u00a0A, Menard\u00a0MT, Conte\u00a0MS et\u00a0al (2022) Surgery or endovascular therapy for chronic limb-threatening ischemia. N\u00a0Engl J Med 387:2305\u20132316","journal-title":"N Engl J Med"},{"key":"5252_CR25","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/S0140-6736(23)00462-2","volume":"401","author":"AW Bradbury","year":"2023","unstructured":"Bradbury\u00a0AW, Moakes\u00a0CA, Popplewell\u00a0M et\u00a0al (2023) A\u00a0vein bypass first versus a\u00a0best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase\u00a03\u00a0trial. Lancet 401:1798\u20131809","journal-title":"Lancet"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-024-05252-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-024-05252-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-024-05252-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T18:03:17Z","timestamp":1722276197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-024-05252-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5252"],"URL":"https:\/\/doi.org\/10.1007\/s00059-024-05252-3","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"15 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>C.\u00a0Espinola-Klein<\/b> macht folgende Angaben: A. Finanzielle Interessen: Kooperationen in Form von Vortragst\u00e4tigkeit, Beratert\u00e4tigkeit, Unterst\u00fctzung von Veranstaltungen mit: Abbott, Amarin, Amgen, Bayer, Boehringer, Bristol-Myers Squibb, Cordis, Daiichi Sankyo, Novartis, Pfizer, Sanofi-Aventis. B. Nichtfinanzielle Interessen: Vorstand Deutsche Gesellschaft f\u00fcr Angiologie, Ausschuss Deutsche Gesellschaft f\u00fcr Innere Medizin.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}